<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05074056</url>
  </required_header>
  <id_info>
    <org_study_id>31070</org_study_id>
    <nct_id>NCT05074056</nct_id>
  </id_info>
  <brief_title>Ketorolac on Postoperative Pain Reduction in Pediatric Patients With Adenotonsillectomy</brief_title>
  <official_title>Evaluation of Perioperative Usage of Ketorolac on Postoperative Pain Reduction in Pediatric Patients With Adenotonsillectom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Louis University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative pain management in pediatric patient with tonsillectomy is challenging. Despite&#xD;
      being used in many procedures for postoperative pain management, perioperative ketorolac&#xD;
      usage in pediatric tonsillectomy surgery is very limited. A recent survey shows that only&#xD;
      8.2% of anesthesiologists use NSAIDS for perioperative management of children with OSA&#xD;
      undergoing adenotonsillectomy. We propose to conduct a perspective, randomized study to&#xD;
      investigate the opioid-sparing effect of perioperative ketorolac in pediatric patients who&#xD;
      have tonsillectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adenotonsillectomy is one of the most frequent surgeries performed in pediatric population in&#xD;
      the United States mainly due to conditions such as sleep disordered breathing, and&#xD;
      tonsillitis. However, postoperative pain control following adenotonsillectomy still offers&#xD;
      great challenges to anesthesiologists. Postoperative pain has been the most common adverse&#xD;
      effect in post-anesthesia care unit (PACU) for children after tonsillectomy, and&#xD;
      postoperative pain is also correlated with emergence agitation, ileus, delayed mobilization,&#xD;
      prolonged hospital stays, the development of chronic pain syndromes, as well as postoperative&#xD;
      nausea and vomiting (PONV). Therefore, benefits of effective pain control are many fold:&#xD;
      improving patient/family satisfaction, reducing the risk of postoperative bleeding due to&#xD;
      emergence agitation, decreasing incidence of PONV, and cutting down clinical symptoms related&#xD;
      to opioid overdose.&#xD;
&#xD;
      To better control postoperative pain, pre-operative and intraoperative pain managements have&#xD;
      been the key. Preventative analgesic interventions may provide protection against the&#xD;
      development of persistent postoperative pain. Although opioid derivatives such as fentanyl&#xD;
      and morphine are mainstays for the perioperative management of post-tonsillectomy pain,&#xD;
      opioid consumption is positively correlated with clinical adverse effects such as PONV,&#xD;
      opioid overdose, and over-sedation. Especially for pediatric patients with severe obstructive&#xD;
      sleep apnea (OSA), opioids may depress ventilation and lead to further airway obstruction,&#xD;
      result in desaturation of blood oxygen, and even death. Multi-modal pain control including&#xD;
      using of combinations of opioids with selective alpha2-adrenergic agonist such as&#xD;
      dexmedetomidine, nonsteroidal anti-inflammatory drugs (NSAIDS), such as ketorolac, are&#xD;
      frequently used for analgesia in children undergoing tonsillectomy. Dexmedetomidine is a&#xD;
      selective alpha-2 adrenergic receptor agonist that directly acts on the peripheral nervous&#xD;
      system, causing a dose-dependent inhibition of C-fibers and AÎ±-fibers. Non-selective NSAIDS&#xD;
      have been shown to function both peripherally and centrally in nociception. NSAIDs act at the&#xD;
      peripheral nociceptors by blocking the cyclooxygenase (COX) enzyme that inhibits the&#xD;
      conversion of arachidonic acid to prostaglandins, thereby preventing the sensitization of&#xD;
      pain receptors in response to injury. Centrally, NSAIDs inhibit prostaglandin E2 (PGE2)&#xD;
      production in the spinal dorsal horn via COX-2, activate medullary and cortical brain regions&#xD;
      involved in the descending inhibitory pain cascade, result in central sensitization and a&#xD;
      lower pain threshold in the surrounding uninjured tissue.&#xD;
&#xD;
      Among NSAIDS, Ketorolac tromethamine (Toradol) is the first approved for parenteral use in&#xD;
      1990 in the United States. Despite its variety of clinical indications, it is mainly&#xD;
      administered for the management of postoperative pain It has strong analgesic properties,&#xD;
      with a dose of 30 mg intramuscular (IM) offering similar analgesia as 12 mg of morphine. The&#xD;
      strong analgesic properties of reducing opioid requirements make it a good candidate in&#xD;
      multi-modal pain management of post-tonsillectomy pain. Unlike opioid analgesics, ketorolac&#xD;
      does not depress ventilation, and is not associated with nausea and vomiting, urinary&#xD;
      retention or sedation. When combined with an opioid, ketorolac exhibits significant&#xD;
      opioid-sparing effects, allowing a lower dosage of opioid to be used. Clinical studies in&#xD;
      children and adults show that the synergistic action of ketorolac and opioids improves the&#xD;
      degree and quality of pain relief, and reduces the incidence of opioid-related adverse&#xD;
      effects such as respiratory depression, PONV, and ileus. However, similar to other&#xD;
      non-selective Cox enzyme inhibitors, ketorolac has several adverse effects including&#xD;
      gastrointestinal (GI) bleeding, renal impairment, liver dysfunction, possible allergic&#xD;
      reactions, and disruption of platelet aggregation through the inhibition of thromboxane A.&#xD;
      However, the evidence of increased bleeding is conflicting. Philips-Reed et al conducted a&#xD;
      metanalysis suggested that there was no consensus on the increased risk of bleeding when&#xD;
      NSAIDS such as ketorolac are given to pediatric patients undergoing tonsillectomy. There are&#xD;
      other analyses support their conclusion.&#xD;
&#xD;
      Despite of these findings, perioperative ketorolac usage, especially in pediatric&#xD;
      tonsillectomy surgery, is very limited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective Randomized Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain management</measure>
    <time_frame>two hours</time_frame>
    <description>Change in pain score using the Wong-Baker FACES Pain Rating Scale (0-10 scale with 0 being &quot;no hurt&quot; and 10 being &quot;hurts worst&quot;) and 0-10 Numeric Pain Intensity Scale (0-10 scale with 0 being &quot;no pain&quot; and 10 being &quot;Worst pain&quot;).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adenotonsillar Hypertrophy</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Sleep-Disordered Breathing</condition>
  <condition>Acute Post Operative Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A double-blinded number of children will get one dose of intravenous 0.5 mg/kg (max dose 30mg) ketorolac intraoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A double-blinded number of children will get one dose of intravenous placebo intraoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>We will administer intraoperative ketorlac.</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adenotonsillar hypertrophy&#xD;
&#xD;
          -  ASA II&#xD;
&#xD;
          -  Otherwise healthy child&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child &lt; 3 years old and &gt; 18 years old&#xD;
&#xD;
          -  Severe Obstructive sleep apnea&#xD;
&#xD;
          -  Chronic Kidney disease&#xD;
&#xD;
          -  Chronic Liver Disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea G Zepeda, M.D.</last_name>
    <phone>314-577-5622</phone>
    <email>andrea.zepeda@health.slu.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pin Yue, C.A.A.</last_name>
    <phone>314-577-5622</phone>
    <email>pin.yue@health.slu.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Franz AM, Dahl JP, Huang H, Verma ST, Martin LD, Martin LD, Low DK. The development of an opioid sparing anesthesia protocol for pediatric ambulatory tonsillectomy and adenotonsillectomy surgery-A quality improvement project. Paediatr Anaesth. 2019 Jul;29(7):682-689. doi: 10.1111/pan.13662. Epub 2019 Jun 19.</citation>
    <PMID>31077491</PMID>
  </reference>
  <reference>
    <citation>Tan GX, Tunkel DE. Control of Pain After Tonsillectomy in Children: A Review. JAMA Otolaryngol Head Neck Surg. 2017 Sep 1;143(9):937-942. doi: 10.1001/jamaoto.2017.0845. Review.</citation>
    <PMID>28662233</PMID>
  </reference>
  <reference>
    <citation>Scalzitti NJ, Sarber KM. Diagnosis and perioperative management in pediatric sleep-disordered breathing. Paediatr Anaesth. 2018 Nov;28(11):940-946. doi: 10.1111/pan.13506. Epub 2018 Oct 3. Review.</citation>
    <PMID>30281185</PMID>
  </reference>
  <reference>
    <citation>Tang C, Xia Z. Dexmedetomidine in perioperative acute pain management: a non-opioid adjuvant analgesic. J Pain Res. 2017 Aug 11;10:1899-1904. doi: 10.2147/JPR.S139387. eCollection 2017. Review.</citation>
    <PMID>28860845</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Bah M. NSAIDs in the Treatment of Postoperative Pain. Curr Pain Headache Rep. 2016 Nov;20(11):62. Review.</citation>
    <PMID>27841015</PMID>
  </reference>
  <reference>
    <citation>Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996;52 Suppl 5:13-23. Review.</citation>
    <PMID>8922554</PMID>
  </reference>
  <reference>
    <citation>Vadivelu N, Chang D, Helander EM, Bordelon GJ, Kai A, Kaye AD, Hsu D, Bang D, Julka I. Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review. Anesthesiol Clin. 2017 Jun;35(2):e1-e20. doi: 10.1016/j.anclin.2017.01.001. Epub 2017 Apr 14. Review.</citation>
    <PMID>28526155</PMID>
  </reference>
  <reference>
    <citation>Maslin B, Lipana L, Roth B, Kodumudi G, Vadivelu N. Safety Considerations in the Use of Ketorolac for Postoperative Pain. Curr Drug Saf. 2017;12(1):67-73. doi: 10.2174/1574886311666160719154420. Review.</citation>
    <PMID>27440142</PMID>
  </reference>
  <reference>
    <citation>Forrest JB, Heitlinger EL, Revell S. Ketorolac for postoperative pain management in children. Drug Saf. 1997 May;16(5):309-29. Review.</citation>
    <PMID>9187531</PMID>
  </reference>
  <reference>
    <citation>Forrest JB, Camu F, Greer IA, Kehlet H, Abdalla M, Bonnet F, Ebrahim S, Escolar G, Jage J, Pocock S, Velo G, Langman MJ, Bianchi PG, Samama MM, Heitlinger E; POINT Investigators. Ketorolac, diclofenac, and ketoprofen are equally safe for pain relief after major surgery. Br J Anaesth. 2002 Feb;88(2):227-33.</citation>
    <PMID>11883386</PMID>
  </reference>
  <reference>
    <citation>Phillips-Reed LD, Austin PN, Rodriguez RE. Pediatric Tonsillectomy and Ketorolac. J Perianesth Nurs. 2016 Dec;31(6):485-494. doi: 10.1016/j.jopan.2015.02.005. Epub 2016 May 5. Review.</citation>
    <PMID>27931700</PMID>
  </reference>
  <reference>
    <citation>Lewis SR, Nicholson A, Cardwell ME, Siviter G, Smith AF. Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy. Cochrane Database Syst Rev. 2013 Jul 18;(7):CD003591. doi: 10.1002/14651858.CD003591.pub3. Review.</citation>
    <PMID>23881651</PMID>
  </reference>
  <reference>
    <citation>Roberts C, Al Sayegh R, Ellison PR, Sedeek K, Carr MM. How Pediatric Anesthesiologists Manage Children with OSA Undergoing Tonsillectomy. Ann Otol Rhinol Laryngol. 2020 Jan;129(1):55-62. doi: 10.1177/0003489419874371. Epub 2019 Sep 5.</citation>
    <PMID>31801377</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Louis University</investigator_affiliation>
    <investigator_full_name>Andrea Zepeda, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

